Udo Vanhoefer
Overview
Explore the profile of Udo Vanhoefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ebert M, Fischbach W, Hollerbach S, Hoppner J, Lorenz D, Stahl M, et al.
Z Gastroenterol
. 2024 Apr;
62(4):535-642.
PMID: 38599580
No abstract available.
2.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P, et al.
United European Gastroenterol J
. 2024 Jan;
12(3):399-411.
PMID: 38284661
Diagnosis and therapy of esophageal carcinoma is challenging and requires a multidisciplinary approach. The purpose of the updated German guideline "Diagnosis and Treatment of Squamous Cell Carcinoma and Adenocarcinoma of...
3.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P, et al.
Z Gastroenterol
. 2023 Jun;
61(6):701-745.
PMID: 37285870
No abstract available.
4.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P, et al.
Z Gastroenterol
. 2023 Jun;
61(6):e209-e307.
PMID: 37285869
No abstract available.
5.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P, et al.
Z Gastroenterol
. 2019 Apr;
57(3):e120.
PMID: 30952167
No abstract available.
6.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P, et al.
Z Gastroenterol
. 2019 Mar;
57(3):336-418.
PMID: 30861559
No abstract available.
7.
Braig F, Marz M, Schieferdecker A, Schulte A, Voigt M, Stein A, et al.
Oncotarget
. 2015 Jun;
6(14):12035-47.
PMID: 26059438
Acquired resistance to epidermal growth factor receptor (EGFR) targeted antibodies represents a clinical challenge in the treatment of gastrointestinal tumors such as metastatic colorectal cancer, but its molecular mechanisms are...
8.
Trarbach T, Przyborek M, Schleucher N, Heeger S, Lupfert C, Vanhoefer U
Invest New Drugs
. 2012 Jul;
31(3):642-52.
PMID: 22763610
Background: To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and...
9.
Arnold D, Fietkau R, Hegewisch-Becker S, Hohler T, Knoefel W, Kubicka S, et al.
Onkologie
. 2011 May;
34 Suppl 3:1-31.
PMID: 21577036
No abstract available.
10.
Trarbach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, et al.
Onkologie
. 2010 Mar;
33(3):89-93.
PMID: 20215798
Background: This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal...